You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Sierra Oncology licenses myelofibrosis candidate from AstraZeneca

Under a new agreement, AstraZeneca will licence AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode, to Sierra Oncology.